Predicting survival in adults with invasive aspergillosis during therapy for hematological malignancies or after hematopoietic stem cell transplantation: Single-center analysis and validation of the Seattle, French, and Strasbourg prognostic indexes

American Journal of Hematology

Volumn 84, Issue 9, 2009, Pages 571-578

  Parody, Rocio ^a   Martino, Rodrigo ^a   Sánchez, Ferran ^a   Subirá, Maricel ^a   Hidalgo, Alberto ^a   Sierra, Jorge ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

STEROID;

ADULT; AGED; ARTICLE; ASPERGILLOSIS; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOCYTOPENIA; NEUTROPENIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SURVIVAL RATE; VALIDATION STUDY;

ADULT; AGED; ASPERGILLOSIS; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 69549118244     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21488     Document Type: Article

References (35)

1. Subirà M, Martino R, Franquet T, et al. Invasive pulmonary aspergillosis in patients with hematologic malignancies: Survival and prognostic factors. Haematologica 2002;87:528-534. (Pubitemid 34533280)
2. Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: The SEIFEM-2004 study. Haematologica 2006;91:1068-1075. (Pubitemid 44208634)
3. Nivoix Y, Velten M, Letscher-Bru V, et al. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis 2008;47:1176-1184.
4. Ribaud P, Chastang C, Latgé JP, et al. Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. Clin Infect Dis 1999;28:322-330. (Pubitemid 29241222)
5. Pagano L, Caira M, Nosari A, et al. Fungal infections in recipients of hematopoietic stem cell transplants: Results of the SEIFEM B-2004 Study-Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis 2007;45:1161-1170. (Pubitemid 47580314)
6. Cordonnier C, Ribaud P, Herbrecht R, et al. Socié té Française de Greffe de Moelle et de Thérapie Cellulaire. Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: A 1-year retrospective study of consecutive patients at French transplantation centers. Clin Infect Dis 2006;42:955-963.
7. Upton A, Kirby KA, Carpenter P, et al. Invasive aspergillosis following hematopoietic cell transplantation: Outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007;44:531-540. (Pubitemid 46233255)
8. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: A meta-analysis. Clin Infect Dis 2006;42:1417-1427.
9. Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: A prospective feasibility study. Clin Infect Dis 2005;41:1242-1250. (Pubitemid 41534660)
10. Busca A, Locatelli F, Barbui A, et al. Usefulness of sequential Aspergillus galactomannan antigen detection combined with early radiologic evaluation for diagnosis of invasive pulmonary aspergillosis in patients undergoing allogeneic stem cell transplantation. Transplant Proc 2006;38:1610-1613. (Pubitemid 43912722)
11. Hidalgo A, Parody R, Martino R, et al. Correlation between high-resolution computed tomography and galactomannan antigenemia in adult hematologic patients at risk for invasive aspergillosis. Eur J Radiol 2009;71:55-60.
12. Martino R, Cortés M, Subirá M, et al. Efficacy and toxicity of intermediate-dose amphotericin B lipid complex as a primary or salvage treatment of fungal infections in patients with hematological malignancies. Leuk Lymph. 2005;46:1429-1435. (Pubitemid 41479584)
13. Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: A randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007;44:1289-1297. (Pubitemid 46717290)
14. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-415. (Pubitemid 34851833)
15. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46:327-360. (Pubitemid 351265310)
16. Jantunen E, Ruutu P, Niskanen L, et al. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplant 1997;19:801-808. (Pubitemid 27207896)
17. Marr KA, Carter RA, Boeckh M, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: Changes in epidemiology and risk factors. Blood 2002 15;100:4358-4366. (Pubitemid 35429674)
18. Martino R, Subirá M, Rovira M, et al. AlloPBSCT infectious/non-infectious complications subcommittees of the Grupo Español de Trasplante Hematopoye ́ tico (GETH). Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: Incidence and risk factors in 395 patients. Br J Haematol 2002;116:475-482.
19. Fukuda T, Boeckh M, Carter RA, et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood. 2003;102:827-833. (Pubitemid 36917771)
20. Thursky K, Byrnes G, Grigg A, et al. Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation. Bone Marrow Transplant 2004;34:115-121. (Pubitemid 39077101)
21. Barnes PD, Marr KA. Risks, diagnosis and outcomes of invasive fungal infections in haematopoietic stem cell transplant recipients. Br J Haematol 2007;139:519-531. (Pubitemid 350043811)
22. Marr KA, Laverdiere M, Gugel A, et al. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005;40:1762-1769. (Pubitemid 40799945)
23. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis 2002;34:7-14. (Pubitemid 33152659)
24. Rámila E, Sureda A, Martino R, et al. Bronchoscopy guided by high-resolution computed tomography for the diagnosis of pulmonary infections in patients with hematologic malignancies and normal plain chest X-ray. Haematologica 2000;85:961-966. (Pubitemid 30769843)
25. Subirà M, Martino R, Rovira M, Vázquez L, Serrano D, De La Cámara R. Clinical applicability of the new EORTC/MSG classification for invasive pulmonary aspergillosis in patients with hematological malignancies and autopsyconfirmed invasive aspergillosis. Ann Hematol 2003;82:80-82. (Pubitemid 36700979)
26. Cornillet A, Camus C, Nimubona S, et al. Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: A 6-year survey. Clin Infect Dis 2006;43:577-584. (Pubitemid 44267116)
27. Woods G, Miceli MH, Grazziutti ML, et al. Serum Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: A study of 56 patients with hematologic cancer. Cancer 2007;110:830-834. (Pubitemid 47257661)
28. Boutboul F, Alberti C, Leblanc T, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: Increasing antigenemia is associated with progressive disease. Clin Infect Dis 2002;34:939-943. (Pubitemid 34229762)
29. Caillot D, Covaillier JF, Bernard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001;19:253-259. (Pubitemid 32063503)
30. Martino R, Viscoli C. Empirical antifungal therapy in patients with neutropenia and persistent or recurrent fever of unknown origin. Br J Haematol 2006;132:138-154.
31. Sipsas NV, Bodey GP, Kontoyiannis DP. Perspectives for the management of febrile neutropenic patients with cancer in the 21st century. Cancer 2005; 103:1103-1113. (Pubitemid 40328079)
32. Bal AM, Gould IM. Empirical antimicrobial treatment for chemotherapy-induced febrile neutropenia. Int J Antimicrob Agents 2007;29:501-509. (Pubitemid 46562508)
33. Subirá M, Martino R, Gómez L et al. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies - A randomized, controlled trial. Eur J Haematol 2004;72:342-347. (Pubitemid 38520732)
34. Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004;39:1563-1571. (Pubitemid 39578526)
35. De Pauw B, Walsh T, Donnelly P et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/ Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813-1821.